B-CELL NON-HODGKIN LYMPHOMA
Clinical trials for B-CELL NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new B-CELL NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for B-CELL NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New daily pill aims to tackle Hard-to-Treat lymphoma
Disease control Not yet recruitingThis study tests an experimental daily pill called HP-002 in people with B-cell non-Hodgkin lymphoma that has come back or stopped responding to treatment. The trial has two parts: first, finding a safe dose, and then checking if the drug can shrink tumors. It includes several ly…
Matched conditions: B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Shanghai Helioson Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New drug candidate SHR-3079 targets Hard-to-Treat lymphoma
Disease control Not yet recruitingThis trial tests a new drug called SHR-3079 in adults with B-cell non-Hodgkin lymphoma whose cancer has not responded to at least one prior standard treatment. The main goals are to check the drug's safety, find the best dose, and get an early look at whether it can shrink tumors…
Matched conditions: B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New Dual-Targeting cell therapy takes aim at Hard-to-Treat blood cancers
Disease control Not yet recruitingThis early-phase study tests a new type of immune cell therapy (CAR T cells) that targets two proteins on cancer cells at once. It is for adults with B-cell non-Hodgkin lymphoma whose cancer has not responded to or has returned after other treatments. The main goal is to find a s…
Matched conditions: B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Medical College of Wisconsin • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Experimental CAR-T therapy GI001 takes aim at tough lymphoma
Disease control Not yet recruitingThis early-phase trial tests a new CAR-T cell therapy called GI001 in 9 adults with relapsed or refractory B-cell lymphoma. Participants receive a single infusion of engineered immune cells designed to attack cancer. The main goals are to check safety and find the right dose, wit…
Matched conditions: B-CELL NON-HODGKIN LYMPHOMA
Phase: EARLY_PHASE1 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Experimental immune cell cocktail targets tough lymphoma
Disease control Not yet recruitingThis early-phase trial tests a new treatment for people with B-cell non-Hodgkin lymphoma that has not responded to at least two prior therapies. Participants receive donor immune cells (NK cells) along with two antibody drugs (rituximab and tafasitamab) and a support drug (IL-2) …
Matched conditions: B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Paolo Caimi, MD • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Scientists hunt for clues to chemo resistance in blood cancer
Knowledge-focused Not yet recruitingThis study collects blood and bone marrow samples from 80 people with B-cell non-Hodgkin lymphoma to explore why some cancers resist chemotherapy. Researchers will analyze the tumor and its environment, and develop lab models to test new treatments. The goal is to uncover resista…
Matched conditions: B-CELL NON-HODGKIN LYMPHOMA
Sponsor: Nantes University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC